Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Working Capital Changes (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Other Working Capital Changes data on record, last reported at -$6.1 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 1717.82% year-over-year to -$6.1 million; the TTM value through Dec 2025 reached $5.7 million, up 278.04%, while the annual FY2025 figure was $5.7 million, 278.04% up from the prior year.
  • Other Working Capital Changes reached -$6.1 million in Q4 2025 per MIRM's latest filing, down from $10.4 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $10.4 million in Q3 2025 and bottomed at -$6.1 million in Q4 2025.
  • Average Other Working Capital Changes over 5 years is $570350.0, with a median of $100000.0 recorded in 2021.
  • The widest YoY moves for Other Working Capital Changes: up 1226.02% in 2025, down 1717.82% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $1.0 million in 2021, then tumbled by 34.76% to $655000.0 in 2022, then soared by 477.1% to $3.8 million in 2023, then plummeted by 90.05% to $376000.0 in 2024, then tumbled by 1717.82% to -$6.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$6.1 million in Q4 2025, $10.4 million in Q3 2025, and -$1.7 million in Q2 2025.